The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity). This is the first treatment approved for inadequately controlled chronic rhinosinusis with nasal polyps.
Did you know you may be able to tell when an asthma episode or attack is about to start before you have trouble breathing? Knowing your early warning signs (or mild symptoms) can be helpful so you can begin asthma treatment as soon as possible.
Did you know pollen might be responsible for your food allergy? If your mouth or throat itch when you eat certain fruit or vegetables, you could have oral allergy syndrome (OAS). And you would have a pollen allergy to thank for that.
On June 11, 2019, in Oakland, California, the Institute for Clinical and Economic Review (ICER) and its California Technology Assessment Forum (CTAF) met to assess the clinical effectiveness and value of treatments for peanut allergy. The review examined two new technologies to induce immune tolerance — Viaskin® Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics) — as well as non-commercialized oral immunotherapy (OIT).
Out of the 25 million people who have asthma, about 60% of them have allergic asthma. If you have allergic asthma, this means allergens trigger asthma symptoms. Immunotherapy may help allergic asthma symptoms.
AAFA applauds the warning the U.S. Department of Transportation (USDOT) issued to American Airlines in response to American Airline’s denial of the right to pre-board a family of a child with food allergies. However, AAFA calls on the USDOT and Congress to take even stronger actions to protect the rights of airline passengers with allergies and all disabilities.